Explore this test

  • Test Details
  • Lab Values
  • Clinical Significance
  • Treatment Options
DOWNLOAD SPECIMEN PREP FLYER

Explore this test

Test Code 884

Test Details

KIF6 Statin Benefit Genotype Test

This test identifies individuals with a gene variant associated with increased risk of coronary heart disease (CHD). Carriers have enhanced CHD risk reduction when treated with statin therapy.

KIF6 is the gene on chromosome 6 that codes for the kinesin superfamily protein which functions to shuttle cell components along microtubules. This test determines whether the subject has the KIF6 variant rs20455 which causes an amino acid substitution at residue 719 where tryptophan is by arginine. This variant, found in about 40% of the population, increases cardiovascular disease risk about 1.5 fold, and this risk can be normalized with statin therapy in some studies.

Reference:

  1. Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 Prospective Trials. The CARE and WOSCOPS Trials. J Am Coll Cardiol. 2008;51:435-443.

Methodology

Real time polymerase chain reaction (PCR)

Patient Preparation

None

Preferred Specimen

1.0 mL whole blood collected in EDTA (Lavender Top)

Transport Temperature

Refrigerated (ship on frozen cold packs)

Stability

Refrigerated: 14 days

Lab Values

Lab Values

KIF6 Statin Benefit Genotype Test

Optimal

  • Genotype T/T

Borderline

  • Genotype C/T
  • Genotype C/C
Test Details
Clinical Significance

Clinical Significance

KIF6 Statin Benefit Genotype Test

Normal CHD Risk

  • Genotype T/T

1.5-Fold Increased CHD Risk

  • Genotype C/T
  • Genotype C/C
Lab Values
Treatment Options

Treatment Options

KIF6 Statin Benefit Genotype Test

C/T

Consider normalizing CHD risk with statin therapy

C/C

Consider normalizing CHD risk with statin therapy

Clinical Significance